Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.26
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.26
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.91 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$764.35M
Enterprise ValueAU$1.58B
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)54.8
Beta0.59
Next Earnings
Aug 25, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.04
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.58
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.13Price Target Upside38.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.15
Revenue Forecast (FY)AU$849.38M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit top-line expansion demonstrates durable demand for imaging services and successful network growth. Over 2–6 months this supports higher throughput, bargaining power with payers, and the ability to fund incremental sites and modality investments without relying solely on cost cuts.
High Gross Margin / Operational EfficiencyVery high gross margins indicate scalable service delivery and strong pricing relative to variable costs. This structural efficiency provides room to absorb SG&A or invest in technology and reporting capabilities, helping sustain profitability once operating leverage and cash conversion improve.
Improved Leverage And Stable Equity BaseReduced leverage improves financial flexibility for capital expenditure and acquisitions across the clinic network. A stable equity base lowers refinancing risk and supports strategic investments in equipment or contract wins that reinforce long-term market position.
Bears Say
Declining Free Cash FlowA sharp drop in free cash flow limits the company's ability to fund capex, repay debt, or sustain distributions without external financing. If the trend persists over months, it can constrain expansion, pressure liquidity cushions, and increase reliance on borrowing for working capital.
Weak Net Profitability And Return On EquityVery low net margins and ROE show limited conversion of revenue into shareholder returns, indicating structural cost or pricing issues. Over time this can hinder reinvestment capacity, weaken investor confidence, and necessitate operational or strategic change to improve capital efficiency.
Utilisation Sensitivity Of Business ModelRevenue and profitability are highly sensitive to patient volumes and utilisation of fixed assets. In the medium term this creates exposure to referral patterns, contract renewals, and cyclical demand; maintaining steady utilisation requires durable hospital contracts and consistent outpatient flow.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$1.91 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$764.35M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 46 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.033 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.13 (38.27% Upside)
AU$3.13 (38.27% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$125.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.13
▲(38.27% Upside)
Technical Analysis
Healius Limited
―
BCAL Diagnostics Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Imagion Biosystems Ltd.
―
Options Prices
Currently, No data available
---








